MA35233B1 - Molecules de liaison bispecifiques se liant à dii4 et ang2 - Google Patents
Molecules de liaison bispecifiques se liant à dii4 et ang2Info
- Publication number
- MA35233B1 MA35233B1 MA36275A MA36275A MA35233B1 MA 35233 B1 MA35233 B1 MA 35233B1 MA 36275 A MA36275 A MA 36275A MA 36275 A MA36275 A MA 36275A MA 35233 B1 MA35233 B1 MA 35233B1
- Authority
- MA
- Morocco
- Prior art keywords
- ang2
- binding
- binding molecules
- dii4
- bispecific binding
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11160920 | 2011-04-01 | ||
| PCT/EP2012/055897 WO2012131076A1 (en) | 2011-04-01 | 2012-03-30 | BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35233B1 true MA35233B1 (fr) | 2014-07-03 |
Family
ID=44314095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36275A MA35233B1 (fr) | 2011-04-01 | 2013-09-27 | Molecules de liaison bispecifiques se liant à dii4 et ang2 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130078247A1 (enExample) |
| EP (1) | EP2694545B1 (enExample) |
| JP (1) | JP2014511682A (enExample) |
| KR (1) | KR20140016345A (enExample) |
| CN (2) | CN103596977B (enExample) |
| AP (1) | AP2013007086A0 (enExample) |
| AR (1) | AR085919A1 (enExample) |
| AU (1) | AU2012234218A1 (enExample) |
| BR (1) | BR112013025294A2 (enExample) |
| CA (1) | CA2827809A1 (enExample) |
| CL (1) | CL2013002622A1 (enExample) |
| CO (1) | CO6801638A2 (enExample) |
| EA (1) | EA201301109A1 (enExample) |
| EC (1) | ECSP13012996A (enExample) |
| MA (1) | MA35233B1 (enExample) |
| MX (1) | MX337115B (enExample) |
| PE (1) | PE20141157A1 (enExample) |
| PH (1) | PH12013502031A1 (enExample) |
| SG (1) | SG193557A1 (enExample) |
| TN (1) | TN2013000389A1 (enExample) |
| TW (2) | TWI535735B (enExample) |
| UY (1) | UY33997A (enExample) |
| WO (1) | WO2012131076A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CA2865464C (en) * | 2012-03-30 | 2022-07-12 | Boehringer Ingelheim International Gmbh | Ang2-binding molecules |
| JP2015532273A (ja) * | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ剤を含む薬学的組み合わせ |
| CA2883807A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| WO2015175375A1 (en) | 2014-05-13 | 2015-11-19 | Short Jay M | Conditionally active biological proteins |
| CN107540747B (zh) * | 2017-08-09 | 2020-01-24 | 苏州大学附属儿童医院 | 抗人dll4单克隆抗体6f12 |
| CN110950967B (zh) * | 2019-12-13 | 2022-05-13 | 山东民康生物科技有限公司 | 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法 |
| CN118251412A (zh) * | 2021-09-10 | 2024-06-25 | 海南康哲维盛科技有限公司 | 抗ang2抗体及其制备方法和应用 |
| CN116444675B (zh) * | 2023-05-11 | 2023-12-22 | 亲和(武汉)生命科技有限责任公司 | 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用 |
| WO2025111816A1 (en) * | 2023-11-28 | 2025-06-05 | Eluminex Biosciences Limited | Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE203767T1 (de) | 1992-08-21 | 2001-08-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| WO2001079444A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
| CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| BRPI0316092B8 (pt) | 2002-11-08 | 2021-05-25 | Ablynx Nv | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos |
| ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| ES2315664T3 (es) | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
| DK1687338T3 (da) | 2003-11-07 | 2011-02-07 | Ablynx Nv | Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| EP3613767A1 (en) * | 2005-05-18 | 2020-02-26 | Ablynx N.V. | Improved nanobodiestm against tumor cecrosis factor-alpha |
| NZ568739A (en) * | 2005-12-16 | 2010-09-30 | Regeneron Pharma | Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists |
| CN101489576A (zh) * | 2006-06-06 | 2009-07-22 | 健泰科生物技术公司 | 用于调节血管发育的组合物和方法 |
| JP2009539384A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法 |
| SG172687A1 (en) * | 2006-06-06 | 2011-07-28 | Genentech Inc | Compositions and methods for modulating vascular development |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CA2663042A1 (en) * | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CN101802015B (zh) * | 2007-03-29 | 2015-05-06 | 根马布股份公司 | 双特异性抗体及其制造方法 |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN102264763B (zh) * | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20110195494A1 (en) * | 2009-10-02 | 2011-08-11 | Boehringer Ingelheim International Gmbh | Dll4-binging molecules |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
-
2012
- 2012-03-29 US US13/433,354 patent/US20130078247A1/en not_active Abandoned
- 2012-03-30 UY UY0001033997A patent/UY33997A/es unknown
- 2012-03-30 CN CN201280026737.XA patent/CN103596977B/zh not_active Expired - Fee Related
- 2012-03-30 EA EA201301109A patent/EA201301109A1/ru unknown
- 2012-03-30 MX MX2013011032A patent/MX337115B/es active IP Right Grant
- 2012-03-30 PE PE2013002157A patent/PE20141157A1/es not_active Application Discontinuation
- 2012-03-30 KR KR1020137028119A patent/KR20140016345A/ko not_active Withdrawn
- 2012-03-30 TW TW101111544A patent/TWI535735B/zh not_active IP Right Cessation
- 2012-03-30 JP JP2014501664A patent/JP2014511682A/ja not_active Ceased
- 2012-03-30 SG SG2013070792A patent/SG193557A1/en unknown
- 2012-03-30 TW TW101111526A patent/TWI551612B/zh active
- 2012-03-30 BR BR112013025294A patent/BR112013025294A2/pt not_active IP Right Cessation
- 2012-03-30 AU AU2012234218A patent/AU2012234218A1/en not_active Abandoned
- 2012-03-30 WO PCT/EP2012/055897 patent/WO2012131076A1/en not_active Ceased
- 2012-03-30 CN CN201610374703.XA patent/CN106046167A/zh active Pending
- 2012-03-30 CA CA2827809A patent/CA2827809A1/en not_active Abandoned
- 2012-03-30 AR ARP120101129A patent/AR085919A1/es unknown
- 2012-03-30 EP EP12711200.1A patent/EP2694545B1/en not_active Not-in-force
- 2012-03-30 AP AP2013007086A patent/AP2013007086A0/xx unknown
-
2013
- 2013-09-12 CL CL2013002622A patent/CL2013002622A1/es unknown
- 2013-09-26 TN TNP2013000389A patent/TN2013000389A1/fr unknown
- 2013-09-27 MA MA36275A patent/MA35233B1/fr unknown
- 2013-09-27 CO CO13230710A patent/CO6801638A2/es unknown
- 2013-09-30 PH PH12013502031A patent/PH12013502031A1/en unknown
- 2013-10-25 EC ECSP13012996 patent/ECSP13012996A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103596977A (zh) | 2014-02-19 |
| TWI535735B (zh) | 2016-06-01 |
| US20130078247A1 (en) | 2013-03-28 |
| KR20140016345A (ko) | 2014-02-07 |
| WO2012131076A1 (en) | 2012-10-04 |
| TN2013000389A1 (en) | 2015-01-20 |
| EP2694545B1 (en) | 2016-08-24 |
| PH12013502031A1 (en) | 2013-12-16 |
| UY33997A (es) | 2012-09-28 |
| EP2694545A1 (en) | 2014-02-12 |
| AU2012234218A1 (en) | 2013-09-05 |
| BR112013025294A2 (pt) | 2017-06-13 |
| TWI551612B (zh) | 2016-10-01 |
| CN106046167A (zh) | 2016-10-26 |
| TW201302797A (zh) | 2013-01-16 |
| CL2013002622A1 (es) | 2014-02-14 |
| AP2013007086A0 (en) | 2013-08-31 |
| TW201302789A (zh) | 2013-01-16 |
| SG193557A1 (en) | 2013-11-29 |
| AR085919A1 (es) | 2013-11-06 |
| CN103596977B (zh) | 2016-07-06 |
| NZ614243A (en) | 2015-04-24 |
| JP2014511682A (ja) | 2014-05-19 |
| MX2013011032A (es) | 2013-12-06 |
| PE20141157A1 (es) | 2014-09-24 |
| CA2827809A1 (en) | 2012-10-04 |
| CO6801638A2 (es) | 2013-11-29 |
| EA201301109A1 (ru) | 2014-08-29 |
| MX337115B (es) | 2016-02-12 |
| ECSP13012996A (es) | 2013-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34979B1 (fr) | Molecules de liaisonbispecifiques se liant a vegf et ang2 | |
| MA35233B1 (fr) | Molecules de liaison bispecifiques se liant à dii4 et ang2 | |
| MA33609B1 (fr) | Molecules de liaison a dll4 | |
| MA33607B1 (fr) | Molécules de liaison bispécifiques pour une thérapie anti-angiogénique | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| MA44547B1 (fr) | Anticorps anti-pd-1,procédé de leur production et de leur utilisation | |
| EA201590613A1 (ru) | Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения | |
| MA56289A (fr) | Mutéines d'interleukine-21 et méthodes de traitement | |
| MA33815B1 (fr) | Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2 | |
| MA37794B1 (fr) | Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires | |
| MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
| EA201492253A1 (ru) | Конструкторы, связывающиеся с ron, и способы их использования | |
| MA46648A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
| IN2014MN01781A (enExample) | ||
| EA200900424A1 (ru) | Человеческие антитела, которые связываются с cxcr4, и их применение | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| MA35659B1 (fr) | Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer | |
| EA200970250A1 (ru) | Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения | |
| EA201492149A1 (ru) | St2-антигенсвязывающие белки | |
| EA201390826A1 (ru) | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA | |
| MA39342B2 (fr) | Anticorps il -21 | |
| EA201890198A1 (ru) | Новые белки, специфичные в отношении lag-3 | |
| MY200710A (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| MA38801B1 (fr) | Nouveaux composés isoindoline ou isoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 |